Why Celgene's Stock Is On Fire and Bristol-Myers Squibb's Is Sinking Today

Graph sketch with a paper rocket on it.

What happened

Shares of the blue-chip biotech Celgene (NASDAQ: CELG) rose by as much as 33.1% in pre-market trading today, while Bristol-Myers Squibb 's (NYSE: BMY) stock sank by more than 15.8%. The catalyst?

Celgene's stock is skyrocketing today in response to a megamerger with Bristol-Myers Squibb. According to the press release, Bristol and Celgene agreed to a cash and stock transaction valued at approximately $74 billion. Once the deal closes, Celgene's shareholders will swap out their shares for one share of Bristol-Myers Squibb, as well as a $50 cash payment for each share of Celgene. That amount equates to a 53.7% premium compared to where the biotech's stock closed yesterday.

So what

Celgene's shares have been in a tailspin over the past year due to concerns about management's ability to diversify the company's revenue stream ahead of Revlimid's date with the patent cliff . In fact, Celgene's shares were trading near a five-year low prior to this merger. Long story short, investors had clearly lost confidence in Celgene's growth story, suggesting that this merger might have been a wise move -- at least from a near-term valuation standpoint.

Now what

All that being said, this merger may not sit particularly well with some of Celgene's shareholders. After all, the biotech is being sold at a staggering 54% discount relative to its former highs reached less than two years ago. Fortunately, Celgene's shareholders will receive an equity stake in the new combined entity.

But the glaring counterpoint to this consolation prize is that megamergers have rarely created much in the way of value for pharma investors over the years -- a fact that may explain why Bristol's shareholders are hitting the exits this morning.

Are these two struggling biopharma behemoths stronger together? The answer to that $74 billion question won't become apparent until the merger is complete. But Bristol's shareholders don't appear to be particularly optimistic -- even though they seem to be getting Celgene and its top-notch clinical pipeline on the cheap.

10 stocks we like better than Bristol-Myers Squibb

When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor , has quadrupled the market.*

David and Tom just revealed what they believe are the 10 best stocks for investors to buy right now... and Bristol-Myers Squibb wasn't one of them! That's right -- they think these 10 stocks are even better buys.

Click here to learn about these picks!

*Stock Advisor returns as of November 14, 2018

George Budwell owns shares of Celgene. The Motley Fool owns shares of and recommends Celgene. The Motley Fool has a disclosure policy .

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

More Related Articles

Sign up for Smart Investing to get the latest news, strategies and tips to help you invest smarter.